The US FDA has approved of Enzon Pharmaceuticals, Inc.'s (ENZN) supplemental Biologics License Application (sBLA) for Oncaspar (pegaspargase), a multi-agent chemotherapeutic regimen for the first-line treatment of patients with acute lymphoblastic leukemia (ALL).
Oncaspar, a PEG enhanced version of L-asparaginase, had previously been indicated for patients with ALL who require L-asparaginase in their treatment, but developed hypersensitivity to the native forms.
It also offers the advantage over unmodified L-asparaginase in that the dosing regimen that allows for administration every 14 days, compared to twice weekly using unmodified L-asparaginase.
Source: Enzon press release
Comment Preview